ImmunityBio Inc. Stock
ImmunityBio Inc. Stock
Pros and Cons of ImmunityBio Inc. in the next few years
Pros
Cons
Performance of ImmunityBio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ImmunityBio Inc. | -2.230% | -1.599% | 33.408% | 172.207% | 308.818% | 442.966% | -73.755% |
| Heron Therapeutics Inc. | 3.360% | -9.054% | -19.476% | -63.319% | -29.668% | -64.362% | -94.461% |
| Evolus Inc | 0.920% | -4.783% | 23.034% | -63.193% | -19.633% | -44.204% | -57.164% |
| Sangamo Therapeutics Inc. | -1.590% | -5.478% | -2.575% | -63.362% | -4.803% | -83.604% | -96.557% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of ImmunityBio, a company operating in the Biotechnology & Medical Research sector, the overall impression is that of a company grappling with significant challenges. Key metrics such as earnings, profitability, and valuation ratios suggest a period of struggle, which may be indicative of a firm still in the development stages of its products. This analysis aims to break down both the merits and downfalls of the current financial landscape to better understand ImmunityBio's potential trajectory.
Market Capitalization
Revenue Generation
Comments
News
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies
Oncology is the largest therapeutic area in the biopharma industry, in terms of sales. The rapid rise in recent years of drugs to treat diabetes and manage weight loss might disrupt the traditional
Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%
ImmunityBio (NASDAQ:IBRX), a developer of cancer and infectious-disease immunotherapies, closed Monday at $9.83, up 12.99%. The stock moved higher after earnings highlighted 700% ANKTIVA revenue